Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$794.70 -2.0%	$757.32	$510.05 ▼ $934.62	$50.44B	0.46	287,217 shs	248,159 shs
GNMSF Genmab A/S	$270.00 +3.4%	$275.60	$188.80 ▼ $352.00	$16.07B	0.82	1,185 shs	297 shs
TAK Takeda Pharmaceutical	$16.54 -0.1%	$17.90	$12.99 ▼ $18.90	$52.70B	-0.06	2.67 million shs	2.13 million shs
TEVA Teva Pharmaceutical Industries	$35.86 +1.5%	$31.19	$14.99 ▼ $37.35	$40.65B	0.86	6.50 million shs	6.25 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.43%	+2.54%	+6.47%	-6.60%	+21.02%
GNMSF Genmab A/S	+1.89%	+5.78%	+1.89%	-18.34%	+22.44%
TAK Takeda Pharmaceutical	-0.49%	+0.91%	-11.65%	-6.69%	+7.57%
TEVA Teva Pharmaceutical Industries	+2.47%	+13.34%	+19.09%	+2.62%	+118.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$794.70 -2.0%	$757.32	$510.05 ▼ $934.62	$50.44B	0.46	287,217 shs	248,159 shs
GNMSF Genmab A/S	$270.00 +3.4%	$275.60	$188.80 ▼ $352.00	$16.07B	0.82	1,185 shs	297 shs
TAK Takeda Pharmaceutical	$16.54 -0.1%	$17.90	$12.99 ▼ $18.90	$52.70B	-0.06	2.67 million shs	2.13 million shs
TEVA Teva Pharmaceutical Industries	$35.86 +1.5%	$31.19	$14.99 ▼ $37.35	$40.65B	0.86	6.50 million shs	6.25 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.43%	+2.54%	+6.47%	-6.60%	+21.02%
GNMSF Genmab A/S	+1.89%	+5.78%	+1.89%	-18.34%	+22.44%
TAK Takeda Pharmaceutical	-0.49%	+0.91%	-11.65%	-6.69%	+7.57%
TEVA Teva Pharmaceutical Industries	+2.47%	+13.34%	+19.09%	+2.62%	+118.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,016.22	27.87% Upside
GNMSF Genmab A/S	0.00	N/A	N/A	N/A
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$41.56	15.87% Upside

Current Analyst Ratings Breakdown

Latest GNMSF, TAK, ARGX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2026	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $40.00
4/30/2026	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $42.00
4/30/2026	TEVA Teva Pharmaceutical Industries	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$41.00 ➝ $42.00
4/30/2026	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $45.00
4/29/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
4/20/2026	ARGX argenex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
4/20/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
4/9/2026	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $42.00
4/8/2026	TAK Takeda Pharmaceutical	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/3/2026	ARGX argenex	Glj Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
4/2/2026	ARGX argenex	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$1,060.00 ➝ $1,014.00

(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	11.63	$20.90 per share	38.02	$118.34 per share	6.72
GNMSF Genmab A/S	$3.72B	4.47	$16.19 per share	16.68	$88.49 per share	3.05
TAK Takeda Pharmaceutical	$30.09B	1.75	$3.18 per share	5.21	$14.39 per share	1.15
TEVA Teva Pharmaceutical Industries	$17.26B	2.39	$3.78 per share	9.48	$7.16 per share	5.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$19.52	40.71	24.98	1.33	30.42%	38.51%	32.59%	5/7/2026 (Estimated)
GNMSF Genmab A/S	$963M	$15.48	17.44	N/A	N/A	25.89%	17.35%	11.69%	5/7/2026 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.24	68.94	13.03	N/A	2.58%	10.60%	5.21%	5/13/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$1.33	26.97	11.80	3.42	9.01%	43.53%	8.19%	N/A

Latest GNMSF, TAK, ARGX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	Q4 2026	TAK Takeda Pharmaceutical	-$0.0754	N/A	N/A	N/A	$7.17 billion	N/A
5/7/2026	Q1 2026	ARGX argenex	$5.16	N/A	N/A	N/A	$1.31 billion	N/A
5/7/2026	N/A	GNMSF Genmab A/S	$1.56	N/A	N/A	N/A	$905.77 million	N/A
4/29/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	$0.50	$0.53	+$0.03	$0.31	$3.79 billion	$3.98 billion
3/31/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.53	N/A	$0.31	N/A	$3.98 billion
2/26/2026	Q4 2025	ARGX argenex	$6.05	$8.02	+$1.97	$8.02	$1.30 billion	$1.32 billion
2/17/2026	Q4 2025	GNMSF Genmab A/S	$3.10	$0.55	-$2.55	$0.55	$1.05 billion	$1.06 billion
2/14/2026	Q4 2025	ARGX argenex	N/A	$8.02	N/A	$8.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
GNMSF Genmab A/S	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.50	3.02%	-2.41%	208.33%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.23	4.87
GNMSF Genmab A/S	0.86	2.02	2.01
TAK Takeda Pharmaceutical	0.56	1.19	0.65
TEVA Teva Pharmaceutical Industries	1.70	1.01	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
GNMSF Genmab A/S	N/A
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
GNMSF Genmab A/S	1.54%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.19 million	60.68 million	Optionable
GNMSF Genmab A/S	3,029	61.57 million	60.62 million	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.15 billion	1.14 billion	Optionable

GNMSF, TAK, ARGX, and TEVA Headlines

Recent News About These Companies

Teva Pharmaceutical Industries (NYSE:TEVA) EVP Christine Fox Sells 21,258 Shares

May 5 at 6:14 AM | americanbankingnews.com

Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells 21,258 Shares

May 5 at 4:35 AM | insidertrades.com

Teva Pharmaceutical Industries (NYSE:TEVA) Insider Mark Sabag Sells 144,180 Shares of Stock

May 5 at 4:21 AM | americanbankingnews.com

How The Investment Story For Teva Pharmaceutical Industries (TEVA) Is Shifting With New Analyst Focus

May 4 at 8:00 PM | finance.yahoo.com

Teva to Present at the BofA Securities Health Care Conference

May 4 at 8:00 PM | finance.yahoo.com

Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells 21,258 Shares of Stock

May 4 at 4:50 PM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Insider Mark Sabag Sells 144,180 Shares

May 4 at 4:50 PM | marketbeat.com

Teva to Present at the BofA Securities Health Care Conference

May 4 at 4:30 PM | globenewswire.com

Strs Ohio Cuts Stake in Teva Pharmaceutical Industries Ltd. $TEVA

May 4 at 6:37 AM | marketbeat.com

Teva Pharmaceutical Industries Q1 Earnings: AUSTEDO Surges as Teva Plots $700M Emalex Buyout

May 4 at 5:42 AM | marketbeat.com

Teva Pharmaceutical Industries' (TEVA) "Overweight" Rating Reiterated at Piper Sandler

May 3 at 5:25 AM | americanbankingnews.com

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $45.00

May 3 at 5:25 AM | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Brokerages

May 3 at 4:45 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $40.00

May 3 at 3:42 AM | americanbankingnews.com

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $42.00

May 3 at 3:42 AM | americanbankingnews.com

Teva (TEVA) Enters a New $700 Million Acquisition Deal

May 2, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Q1 Earnings Call Highlights

May 2, 2026 | marketbeat.com

Wall Street Zen Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Hold

May 2, 2026 | marketbeat.com

Mega deal: Teva acquires Emalex for approximately $900 million

May 1, 2026 | jpost.comJ

75,000 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Nkcfo LLC

May 1, 2026 | marketbeat.com

Jennison Associates LLC Invests $47.86 Million in Teva Pharmaceutical Industries Ltd. $TEVA

May 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GNMSF, TAK, ARGX, and TEVA Company Descriptions

argenex NASDAQ:ARGX

$794.70 -16.39 (-2.02%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$794.91 +0.21 (+0.03%)

As of 05/5/2026 05:53 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Genmab A/S OTCMKTS:GNMSF

$270.00 +9.00 (+3.45%)

As of 05/5/2026 09:51 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Takeda Pharmaceutical NYSE:TAK

$16.54 -0.02 (-0.10%)

Closing price 05/5/2026 03:59 PM Eastern

Extended Trading

$16.49 -0.05 (-0.33%)

As of 05/5/2026 06:57 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$35.86 +0.51 (+1.45%)

Closing price 05/5/2026 03:59 PM Eastern

Extended Trading

$36.16 +0.29 (+0.81%)

As of 04:12 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNMSF, TAK, ARGX, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNMSF, TAK, ARGX, and TEVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNMSF, TAK, ARGX, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNMSF, TAK, ARGX, and TEVA Company Descriptions

argenex NASDAQ:ARGX

Genmab A/S OTCMKTS:GNMSF

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNMSF, TAK, ARGX, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNMSF, TAK, ARGX, and TEVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNMSF, TAK, ARGX, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNMSF, TAK, ARGX, and TEVA Company Descriptions

argenex NASDAQ:ARGX

Genmab A/S OTCMKTS:GNMSF

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools